Close Menu

NEW YORK — British liquid biopsy developer Angle reported on Thursday a 39 percent year-over-year drop in revenues for the first half of 2020 as the SARS-CoV-2 pandemic impacted use of its flagship Parsortix cell-sorting system.

For the six-month period ended June 30, Angle's revenues fell to £235,000 ($303,962) from £384,000, which the company attributed to the pandemic-related shutdown of research projects of many of its Parsortix customers.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.